Aging :: No proof that growth hormone therapy makes you live longer

Surveyors of anti-aging elixirs tout human growth hormone as a remedy for all things sagging-from skin to libidos — and claim it can even prevent or reverse aging. But researchers at the Stanford University School of Medicine say there’s no evidence to suggest that this purported fountain of youth has any more effect than a trickle of tap water when it comes to fending off Father Time.

Alzheimer’s Disease :: Testosterone therapy prevents Alzheimer’s disease

Researchers at the University of Southern California have discovered a direct link between loss of testosterone and the development of an Alzheimer’s-like disease in mice. They also discovered that testosterone treatment slows progression of the disease.The study, published in the Dec. 20 issue of the Journal of Neuroscience, predicts that testosterone-based hormone therapy may be useful in the treatment and prevention of Alzheimer?s disease in aging men.

Alzheimer’s Disease :: Androgen therapy slows Alzheimer’s disease progress

Experiments on mouse models of Alzheimer’s disease suggest that treatment with male sex hormones might slow its progression. The findings, published in the Dec. 20 issue of the Journal of Neuroscience, provide new insight into the relationship between testosterone loss and AD, which affects 4.5 million Americans.

Menopause :: Black cohosh does not relieve menopausal hot flashes – Group Health

The herbal supplement black cohosh does not relieve hot flashes among women going through menopause. In this double-blinded randomized controlled trial of 351 women, researchers found no significant difference between the numbers of hot flashes in women taking various forms of black cohosh compared to women taking a placebo. Hormone therapy, on the other hand, significantly reduced the frequency of hot flashes.

Breast Cancer :: Few early-stage breast cancer patients follow hormonal therapy plan

Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly, according to a study conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals.